3 August 2015
Cambridge, MA – CluePoints, a leading provider of Centralized Statistical Monitoring (CSM) solutions for clinical trials, has today announced that its Chief Commercial Officer, Patrick Hughes, has been honored by PharmaVOICE as one of the 100 most inspiring people in the life sciences industry. Patrick was recognized for his pioneering work in risk-based monitoring (RBM) and dedication to challenging the industry’s traditional practices and processes when it comes to data analysis in clinical trials.
The prestigious awards scheme, which has been running since 2005, celebrates exceptional professionals in the life-sciences industry who provide inspiration to their peers, colleagues, and companies through their innovative and motivational approaches to addressing the industry’s myriad of challenges.
“I am delighted to have been named in this year’s PharmaVOICE 100,” commented Patrick Hughes. “As well as it being a proud moment for me personally, it’s also a real testament to the relentless hard work and dedication of the entire team. Over recent years, the unwavering commitment of everyone at CluePoints and our shared belief that we could make a real difference has helped drive an industry-wide shift towards RBM practices, and really inspired the industry to step away from the traditional and embrace new approaches to monitoring.”
Commenting on Patrick’s recognition, Francois Torche, CluePoints’ CEO, said: “Having worked with many experts across the field, Patrick’s combination of outstanding business acumen, global commercial expertise and dedication to helping his customers and colleagues achieve their goals, is what makes him really stand out. At CluePoints he has been key in building global awareness of the value of CSM and really getting the industry to sit-up and take notice of a new way of thinking.”
For further information on CluePoints’ solutions, please visit www.CluePoints.com
CluePoints® is a Central Statistical Monitoring solution that has been designed and perfected over the last 10 years. It employs unique statistical algorithms to determine the quality, accuracy and integrity of clinical trial data both during and after study conduct. Aligned with guidance from the FDA and EMA, CluePoints® is deployed to support traditional on-site monitoring and to drive a risk-based monitoring strategy. The value of using CluePoints® lies in its powerful and timely ability to identify anomalous data and site errors allowing improvement in clinical data quality, optimization of on-site monitoring and a significant reduction in overall regulatory submission risk.
Patrick Hughes – Chief Commercial Officer, CluePoints
+44 (0) 7703 532 749